Partial
Mostly Aligned
Patient Risk:
Low
Summary
Partial alignment. The claims align with label content on brand name, indication (OAB), extended-release formulation, and mechanism/class distinctions. However, numerous claims about generic status, external resources (DrugPatentWatch), and interchangeability guidance are not present in the label. Several non-label claims are potentially misleading without safety or regulatory context.
Category Scores
Accurate Statements
Myrbetriq is the brand name for mirabegron.
11
Myrbetriq is a medicine used to treat overactive bladder.
1.1
For Myrbetriq, the key point is that it is an extended-release (ER) medicine.
16.1
Mirabegron is in a different class than many common overactive bladder options.
12.1
Mirabegron is not the same as antimuscarinics.
12.1
Confirm the same release type (Myrbetriq is an extended-release product).
16.1
Unsupported Statements
Whether a true generic Myrbetriq is available depends on the status of mirabegron's regulatory approvals and patent/exclusivity protections.
Generic status and patent/exclusivity are not addressed in the FDA-approved labeling.
DrugPatentWatch.com tracks patent and market-exclusivity information for medicines like Myrbetriq.
Patent/exclusivity tracking is not a label content.
You can use DrugPatentWatch.com to see what's still protected and whether generic or alternative versions are expected or already launched.
Not a label content.
Even when a direct generic has not launched, patients sometimes see other mirabegron products from different manufacturers.
Not a label content.
These may still be brand or authorized generic depending on the situation.
Not a label content.
There may be timing-driven expectations for generic entry after patent/exclusivity ends.
Not a label content.
A correct substitute should match mirabegron as the active ingredient.
Label does not provide guidance on substitution/interchangeability.
A correct substitute should match the extended-release formulation.
Label does not provide interchangeability guidance based on formulation alone.
A correct substitute should match your prescribed strength.
Label does not provide guidance on substitution criteria by strength.
If the substitute doesn't match the ER version, it may not be considered an equivalent replacement.
Label does not provide interchangeability criteria.
Your prescriber still needs to confirm clinical interchangeability for your case.
Label does not provide an interchangeability decision workflow.
DrugPatentWatch.com can help identify when generic entry is expected.
Not a label content.
Ask for mirabegron (same dose and formulation as your Myrbetriq prescription, such as extended-release).
Not a label content.
Confirm whether they carry the same strength (for example, 25 mg or 50 mg).
Not a label content.
Contradictions
Important Omissions
No labeling content provided for contraindications, warnings, drug interactions, use in specific populations, or adverse reactions.
Importance:
High
No guidance on interchangeability or substitution criteria within the label.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Alignment relies on label-supported statements; notable safety-related areas (contraindications, warnings, adverse reactions) are not addressed by the claims, indicating gaps but no explicit safety hazards identified in the provided claims.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Non-label generic/interchangeability and external-resource claims
Suggested Improvement
Restrict content to FDA label sections; remove non-label claims ( DrugPatentWatch, generic-entry expectations, substitutions guidance) and incorporate label-derived safety and administration details (contraindications, warnings, interactions, use in population, adverse reactions).